Metastatic Malignant Peripheral Nerve Sheath Tumor With NF1 Successfully Treated With 'Gradual Subtraction' ICE Chemotherapy

被引:10
作者
Wang, Yiqing [1 ,2 ]
Katagiri, Hirohisa [1 ]
Murata, Hideki [1 ]
Wasa, Junji [1 ]
Miyagi, Michihito [1 ]
Kakuda, Yuko [3 ]
Takahashi, Mitsuru [1 ]
机构
[1] Shizuoka Canc Ctr Hosp, Div Orthopaed Oncol, 1007 Shimonagakubo,Nagaizumi Cho, Shizuoka 4118777, Japan
[2] Third Peoples Hosp Hangzhou, Dept Oncol, Hangzhou, Peoples R China
[3] Shizuoka Canc Ctr Hosp, Div Pathol, Shizuoka, Japan
关键词
Neurofibromatosis type I; NF1; ICE chemotherapy; malignant peripheral nerve sheath tumor; MPNST; SARCOMA; MANAGEMENT; RADIATION; SURVIVAL; CHILDREN; CANCER; MPNST;
D O I
10.21873/anticanres.14110
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Prognosis of metastatic malignant peripheral nerve sheath tumor (MPNST) is poor and the role of chemotherapy is controversial. There has been no report of metastatic MPNST with a good prognosis without surgery for metastases. Case Report: A 40-year-old man with neurofibromatosis type 1 (NF1)-related MPNST on his shoulder with multiple lung metastases visited our hospital. After two cycles of chemotherapy with ifosfamide, carboplatin and etoposide (ICE), the primary lesion and lung metastases had shrunk. The primary lesion was resected with negative margins. Subsequently, 'gradual subtraction' ICE was administered, wherein the dose was reduced and the treatment interval was increased. After 14 courses of ICE over a period of 2 years, the lung metastases disappeared; there has been no recurrence for over 12 years. Conclusion: ICE can be an excellent, inexpensive treatment for NF1-related MPNST. 'Gradual subtraction' chemotherapy allowed us to maintain long-term efficacy, induce tumor dormancy, and reduce side-effects.
引用
收藏
页码:1619 / 1624
页数:6
相关论文
共 24 条
  • [1] Malignant peripheral nerve sheath tumor in children: A single-institute retrospective analysis
    An, Hong Yul
    Hong, Kyung Taek
    Kang, Hyoung Jin
    Choi, Jung Yoon
    Hong, CheRy
    Kim, Hyun-young
    Choi, Tae Hyun
    Kang, Chang Hyun
    Kim, Han-Soo
    Cheon, Jung-Eun
    Park, Sung-Hye
    Park, June Dong
    Park, Kyung Duk
    Shin, Hee Young
    [J]. PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2017, 34 (08) : 468 - 477
  • [2] ICE Regimen for Relapsed/Refractory Bone and Soft Tissue Sarcomas in Children
    Aydin, Burca
    Akyuz, Canan
    Varan, Ali
    Yalcin, Bilgehan
    Kurucu, Nilgun
    Kutluk, Tezer
    [J]. REVIEWS ON RECENT CLINICAL TRIALS, 2018, 13 (02) : 126 - 131
  • [3] Metronomic therapy for malignant peripheral nerve sheath tumor in neurofibromatosis type 1
    Chaudhary, Narendra
    Borker, Anupama
    [J]. PEDIATRIC BLOOD & CANCER, 2012, 59 (07) : 1317 - 1319
  • [4] DUCATMAN BS, 1986, CANCER-AM CANCER SOC, V57, P2006, DOI 10.1002/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO
  • [5] 2-6
  • [6] Malignant peripheral nerve sheath tumours in neurofibromatosis 1
    Evans, DGR
    Baser, ME
    McGaughran, J
    Sharif, S
    Howard, E
    Moran, A
    [J]. JOURNAL OF MEDICAL GENETICS, 2002, 39 (05) : 311 - 314
  • [7] Ferner RE, 2002, CANCER RES, V62, P1573
  • [8] Hirbe Angela C., 2017, Sarcoma, V2017, P3761292, DOI 10.1155/2017/3761292
  • [9] The value of 18F-FDG PET/CT in the management of malignant peripheral nerve sheath tumors
    Khiewvan, Benjapa
    Macapinlac, Homer A.
    Lev, Dina
    McCutcheon, Ian E.
    Slopis, John M.
    Al Sannaa, Ghadah
    Wei, Wei
    Chuang, Hubert H.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (09) : 1756 - 1766
  • [10] Kim AeRang, 2017, Sarcoma, V2017, P7429697, DOI 10.1155/2017/7429697